Saturday, January 30, 2021 5:25:14 PM
But, protein folding is even more complex.
Nice, educational video on protein folding. Good intro; but incomplete.
It's claimed or implied that protein folding is solely dependent upon the particular sequence of amino acids in the protein. Doubtless, this a major, even requisite pre-condition. If the wrong amino acids get inserted or substituted, the protein will fold improperly. This is the mechanism of most mutations; a genetics, amino acid sequence problem.
But, in regard to blarcamesine (the Anavex drug) treating various central nervous system (CNS) diseases, which involve or are caused by mis-folded proteins (in most cases, reaction-controlling enzymes), the proteins (enzymes) don't mis-fold because of new genetic, amino acid sequence errors. The genes controlling protein synthesis in people with Alzheimer's disease are the same in childhood as in old age. No Alzheimer's in childhood; but the disease appears with age. Same genes, but waste-clearing proteins abundant in childhood are no longer produced. With age, the enzyme proteins that clear wastes in the neuron mis-fold, or fail to fold altogether. Normally-cleared metabolic wastes accumulate; neuron functions become ever more compromised.
The video failed to tell where protein folding occurs. Most of it happens in, is directed by the mitochondria. Chemical conditions in those organelles have to be just-so. Exactly the proper pH, with sufficient adenosine triphosphate (ATP) to provide the energy driving the folding reactions. Various minerals, particularly calcium ions, also have to be present and available in precise concentrations, at precise locations. If any of these protein folding factors are anomalous, the protein, an essential reaction-controlling enzyme, gets literally bent out of shape, and is thereby unable to catalyze its waste-clearing reactions. Wastes accumulate, one of the CNS diseases sets in.
In the neuron, blarcamesine, propitiously, binds to the sigma-1 receptor protein and causes it to function properly and effectively. Among other things, that restores the required, proper chemistry inside the attached mitochondria. Properly-shaped proteins can then, as in youth, be folded. Wastes, once again, can be cleared.
Nice, educational video on protein folding. Good intro; but incomplete.
It's claimed or implied that protein folding is solely dependent upon the particular sequence of amino acids in the protein. Doubtless, this a major, even requisite pre-condition. If the wrong amino acids get inserted or substituted, the protein will fold improperly. This is the mechanism of most mutations; a genetics, amino acid sequence problem.
But, in regard to blarcamesine (the Anavex drug) treating various central nervous system (CNS) diseases, which involve or are caused by mis-folded proteins (in most cases, reaction-controlling enzymes), the proteins (enzymes) don't mis-fold because of new genetic, amino acid sequence errors. The genes controlling protein synthesis in people with Alzheimer's disease are the same in childhood as in old age. No Alzheimer's in childhood; but the disease appears with age. Same genes, but waste-clearing proteins abundant in childhood are no longer produced. With age, the enzyme proteins that clear wastes in the neuron mis-fold, or fail to fold altogether. Normally-cleared metabolic wastes accumulate; neuron functions become ever more compromised.
The video failed to tell where protein folding occurs. Most of it happens in, is directed by the mitochondria. Chemical conditions in those organelles have to be just-so. Exactly the proper pH, with sufficient adenosine triphosphate (ATP) to provide the energy driving the folding reactions. Various minerals, particularly calcium ions, also have to be present and available in precise concentrations, at precise locations. If any of these protein folding factors are anomalous, the protein, an essential reaction-controlling enzyme, gets literally bent out of shape, and is thereby unable to catalyze its waste-clearing reactions. Wastes accumulate, one of the CNS diseases sets in.
In the neuron, blarcamesine, propitiously, binds to the sigma-1 receptor protein and causes it to function properly and effectively. Among other things, that restores the required, proper chemistry inside the attached mitochondria. Properly-shaped proteins can then, as in youth, be folded. Wastes, once again, can be cleared.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
